Mycenax Biotech Inc. (TPEX:4726)

Market Cap	6.97B
Revenue (ttm)	727.40M
Net Income (ttm)	-496.20M
Shares Out	207.11M
EPS (ttm)	-2.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,000
Average Volume	216,510
Open	33.55
Previous Close	33.55
Day's Range	33.40 - 34.30
52-Week Range	27.40 - 51.00
Beta	0.49
RSI	30.80
Earnings Date	Nov 12, 2025

About Mycenax Biotech

Mycenax Biotech Inc. provides biopharmaceutical services and solutions for drug development and production in Taiwan. The company’s services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers plasmid DNA, antibody-drug conjugates, cell and gene therapy, and exosomes products and services. The company was founded in 2001 and is headquartered in Zhubei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 387
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4726

Financial Performance

In 2024, Mycenax Biotech's revenue was 683.92 million, an increase of 4.80% compared to the previous year's 652.62 million. Losses were -467.13 million, -31.59% less than in 2023.